亚洲房颤患者肾功能正常或轻度受损时利伐沙班的最佳剂量
本研究基于韩国国民健康保险数据库,纳入肌酐清除率≥50 mL/min的亚洲非瓣膜性房颤患者,比较利伐沙班20 mg、15 mg与华法林的疗效与安全性。结果显示两种剂量均优于华法林,且按说明书使用20 mg在复合临床结局上优于超说明书使用15 mg。
要点
- CrCl≥50 mL/min的亚洲房颤患者中,利伐沙班20 mg和15 mg均比华法林降低缺血性卒中、大出血和全因死亡风险。
- 利伐沙班20 mg在复合临床结局上优于15 mg(HR 0.852,95%CI 0.735-0.988)。
- CrCl 50-60 mL/min的患者中,利伐沙班20 mg的大出血风险高于15 mg。
核心结论
- 在CrCl≥50 mL/min的亚洲房颤患者中,利伐沙班20 mg和15 mg均比华法林降低缺血性卒中、颅内出血、大出血和全因死亡风险,且不显著增加消化道出血风险。
- 按说明书使用利伐沙班20 mg在复合临床结局上优于超说明书使用15 mg。
研究设计与样本
- 构建三个1:1倾向评分匹配队列:利伐沙班20 mg vs 华法林(n=15 584)、利伐沙班15 mg vs 华法林(n=11 554)、利伐沙班20 mg vs 15 mg(n=10 392)。
主要发现
- 与华法林相比,利伐沙班20 mg和15 mg均显著降低缺血性卒中、大出血(主要经减少颅内出血)和全因死亡风险。
- 与利伐沙班15 mg相比,20 mg的复合临床结局更优(HR 0.852;95%CI 0.735-0.988),该获益在年龄≥80岁和体重<50 kg患者中一致。
- 在CrCl 50-60 mL/min的患者中,利伐沙班20 mg的大出血风险高于15 mg。
临床怎么用
- 对于CrCl≥50 mL/min的亚洲房颤患者,优先按说明书使用利伐沙班20 mg而非超说明书使用15 mg。
- 在CrCl 50-60 mL/min的边缘肾功能患者中,选择利伐沙班20 mg时需权衡大出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Although rivaroxaban 15 mg (R15) was only given to patients with creatinine clearance (CrCl) ≤50 mL/min in the pivotal clinical trial, this dose has been commonly prescribed in Asian patients with nonvalvular atrial fibrillation regardless of renal function. There is a paucity of information on the clinical outcomes of R15 compared with rivaroxaban 20 mg (R20) in patients with CrCl ≥50 mL/min. This study aimed to examine the effectiveness and safety of 2 doses of rivaroxaban in Asian patients with atrial fibrillation and CrCl ≥50 mL/min. Methods- Using the Korean National Health Insurance Service database, patients with atrial fibrillation and normal or mildly impaired renal function (CrCl ≥50 mL/min) and naive to rivaroxaban or warfarin were included from January 2014 to December 2016. Three separate 1:1 propensity score-matched cohorts were conducted: R20 versus warfarin (n=15 584), R15 versus warfarin (n=11 554), and R20 versus R15 (n=10 392). Hazard ratios for ischemic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause death, and composite clinical outcome were analyzed. Results- Compared with warfarin, both R20 and R15 showed significantly lower risk for ischemic stroke, major bleeding (mainly through reduction of intracranial hemorrhage), and all-cause death. Compared with R15, R20 showed better results for the composite clinical outcome (hazard ratio, 0.852; 95% CI, 0.735-0.988). This benefit was consistently observed in patients aged ≥80 years and those <50 kg. R20 was associated with higher risk of major bleeding than R15 in patients with marginal CrCl (50-60 mL/min). Conclusions- Among Asians with atrial fibrillation and CrCl ≥50 mL/min, both R20 and R15 were associated with reduced risk of ischemic stroke, intracranial hemorrhage, major bleeding, and all-cause death without significantly increased risk of gastrointestinal bleeding compared with warfarin. In patients with CrCl ≥50 mL/min, on-label R20 showed better results for the composite clinical outcome compared with off-label R15.
引用
- Lee SR, Choi EK, Han KD, et al. Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function. Stroke. 2019. PMID: 30913984. doi:10.1161/STROKEAHA.118.024210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。